JP2022046676A5 - - Google Patents

Download PDF

Info

Publication number
JP2022046676A5
JP2022046676A5 JP2021212106A JP2021212106A JP2022046676A5 JP 2022046676 A5 JP2022046676 A5 JP 2022046676A5 JP 2021212106 A JP2021212106 A JP 2021212106A JP 2021212106 A JP2021212106 A JP 2021212106A JP 2022046676 A5 JP2022046676 A5 JP 2022046676A5
Authority
JP
Japan
Prior art keywords
growth factor
protein
factor
therapeutic protein
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021212106A
Other languages
English (en)
Japanese (ja)
Other versions
JP7258999B2 (ja
JP2022046676A (ja
Filing date
Publication date
Priority claimed from JP2020196260A external-priority patent/JP7054407B2/ja
Application filed filed Critical
Publication of JP2022046676A publication Critical patent/JP2022046676A/ja
Publication of JP2022046676A5 publication Critical patent/JP2022046676A5/ja
Application granted granted Critical
Publication of JP7258999B2 publication Critical patent/JP7258999B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021212106A 2010-07-30 2021-12-27 オキシム連結のための求核触媒 Active JP7258999B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36918610P 2010-07-30 2010-07-30
US61/369,186 2010-07-30
JP2020196260A JP7054407B2 (ja) 2010-07-30 2020-11-26 オキシム連結のための求核触媒

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020196260A Division JP7054407B2 (ja) 2010-07-30 2020-11-26 オキシム連結のための求核触媒

Publications (3)

Publication Number Publication Date
JP2022046676A JP2022046676A (ja) 2022-03-23
JP2022046676A5 true JP2022046676A5 (https=) 2022-06-03
JP7258999B2 JP7258999B2 (ja) 2023-04-17

Family

ID=44629987

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2013521998A Active JP6325818B2 (ja) 2010-07-30 2011-07-29 オキシム連結のための求核触媒
JP2015118007A Withdrawn JP2015164958A (ja) 2010-07-30 2015-06-11 オキシム連結のための求核触媒
JP2017099807A Withdrawn JP2017137358A (ja) 2010-07-30 2017-05-19 オキシム連結のための求核触媒
JP2019064338A Withdrawn JP2019116501A (ja) 2010-07-30 2019-03-28 オキシム連結のための求核触媒
JP2019064337A Active JP6757823B2 (ja) 2010-07-30 2019-03-28 オキシム連結のための求核触媒
JP2020196260A Active JP7054407B2 (ja) 2010-07-30 2020-11-26 オキシム連結のための求核触媒
JP2021212106A Active JP7258999B2 (ja) 2010-07-30 2021-12-27 オキシム連結のための求核触媒

Family Applications Before (6)

Application Number Title Priority Date Filing Date
JP2013521998A Active JP6325818B2 (ja) 2010-07-30 2011-07-29 オキシム連結のための求核触媒
JP2015118007A Withdrawn JP2015164958A (ja) 2010-07-30 2015-06-11 オキシム連結のための求核触媒
JP2017099807A Withdrawn JP2017137358A (ja) 2010-07-30 2017-05-19 オキシム連結のための求核触媒
JP2019064338A Withdrawn JP2019116501A (ja) 2010-07-30 2019-03-28 オキシム連結のための求核触媒
JP2019064337A Active JP6757823B2 (ja) 2010-07-30 2019-03-28 オキシム連結のための求核触媒
JP2020196260A Active JP7054407B2 (ja) 2010-07-30 2020-11-26 オキシム連結のための求核触媒

Country Status (26)

Country Link
EP (3) EP3505186B1 (https=)
JP (7) JP6325818B2 (https=)
KR (6) KR102229967B1 (https=)
CN (3) CN108079311A (https=)
AR (1) AR082941A1 (https=)
AU (1) AU2011282571C1 (https=)
BR (1) BR112013001611B1 (https=)
CA (1) CA2806684C (https=)
CY (1) CY1121943T1 (https=)
DK (1) DK2598172T3 (https=)
EA (2) EA201691292A1 (https=)
ES (1) ES2731626T3 (https=)
HR (1) HRP20190990T1 (https=)
HU (1) HUE043790T2 (https=)
LT (1) LT2598172T (https=)
MX (1) MX346271B (https=)
NZ (1) NZ605972A (https=)
PL (1) PL2598172T3 (https=)
PT (1) PT2598172T (https=)
RS (1) RS58900B1 (https=)
SG (2) SG10201913078SA (https=)
SI (1) SI2598172T1 (https=)
SM (1) SMT201900351T1 (https=)
TR (1) TR201908836T4 (https=)
TW (1) TWI534152B (https=)
WO (1) WO2012016131A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
TR201908836T4 (tr) * 2010-07-30 2019-07-22 Baxalta GmbH Oksim bağına yönelik nükleofilik katalizörler.
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
MY190257A (en) 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
AU2013204754C1 (en) * 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
WO2017062832A1 (en) 2015-10-08 2017-04-13 Nektar Therapeutics Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist
SG11201804666QA (en) * 2015-12-03 2018-06-28 Baxalta Inc Factor viii with extended half-life and reduced ligand-binding properties
JP7618383B2 (ja) 2016-07-22 2025-01-21 ネクター セラピューティクス オキシム含有リンケージを有する第viii因子部分のコンジュゲート
IL270634B2 (en) 2017-05-15 2025-06-01 Nektar Therapeutics Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
MX2021008797A (es) 2019-01-23 2022-01-31 Regeneron Pharma Tratamiento de afecciones oftalmicas con inhibidores de proteinas relacionadas a angiopoyetina 7 (angptl7).
US11865134B2 (en) 2021-02-26 2024-01-09 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitors
WO2025133203A1 (en) * 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Compounds and methods for a long-lasting pam

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54113492A (en) 1978-02-24 1979-09-05 Sanyo Chem Ind Ltd Preparation of glucoprotein derivative
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター8cの製造方法及びそれに用いる形質転換体
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
CA2124690C (en) 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
WO1994028024A1 (en) * 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5574187A (en) * 1994-10-06 1996-11-12 Uniroyal Chemical Company, Inc. Process of preparing para substituted phenylamines
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
US6531298B2 (en) 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
DE60116137T2 (de) 2000-05-16 2006-08-24 Lipoxen Technologies Ltd. Derivatisierung von proteinen in wässrigem lösungsmittel
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
EP1446438A2 (en) 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
BR0314227A (pt) 2002-09-11 2005-10-25 Fresenius Kabi De Gmbh Derivados de amido de hidroxialquila
PL1620118T3 (pl) 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
CN1863549A (zh) * 2003-08-08 2006-11-15 费森尤斯卡比德国有限公司 通过肟连接基团进行连接的聚合物和蛋白质的缀合物
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
BRPI0412671A (pt) 2003-08-08 2006-10-03 Fresenius Kabi De Gmbh conjugados de um polìmero e uma proteìna ligados por um grupo de ligação de oxima
EP1654290B1 (en) 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
CN1897812B (zh) 2003-12-03 2011-08-17 生物种属学股份公司 糖聚乙二醇化的粒细胞集落刺激因子
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
EP3184551A1 (en) 2004-08-12 2017-06-28 Lipoxen Technologies Limited Sialic acid derivatives
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
CN101163506B (zh) 2004-12-27 2012-09-26 巴克斯特国际公司 聚合物-von Willebrand因子偶联物
HUE025208T2 (en) 2005-06-16 2016-03-29 Nektar Therapeutics Conjugates with degradable binding and polymer reagents useful in the preparation of such conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
WO2008025856A2 (en) * 2006-09-01 2008-03-06 Novo Nordisk Health Care Ag Modified glycoproteins
CN101535339B (zh) * 2006-09-01 2014-11-12 诺沃-诺迪斯克保健股份有限公司 改性糖蛋白
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
WO2009028573A1 (ja) * 2007-08-27 2009-03-05 National University Corporation Nagoya University 血液凝固障害におけるリバビリンの利用
GB0908393D0 (en) * 2009-05-15 2009-06-24 Almac Sciences Scotland Ltd Labelling method
JP5909755B2 (ja) * 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
ES2597954T3 (es) * 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
JP2013500726A (ja) * 2009-07-31 2013-01-10 バイエル・ヘルスケア・エルエルシー 改変第ix因子ポリペプチドおよびその使用
TR201908836T4 (tr) * 2010-07-30 2019-07-22 Baxalta GmbH Oksim bağına yönelik nükleofilik katalizörler.

Similar Documents

Publication Publication Date Title
JP2022046676A5 (https=)
JP2022034075A5 (https=)
JP2020111599A5 (https=)
JP2019116500A5 (https=)
JP2015520163A5 (https=)
JP2019089810A5 (https=)
JP3497175B2 (ja) 一価の(monovalent)抗体フラグメント
HRP20190990T1 (hr) Nukleofilni katalisti za vezanje oksima
Kreitman et al. Purification and characterization of IL6-PE4E, a recombinant fusion of interleukin 6 with Pseudomonas exotoxin
JP5419689B2 (ja) 顆粒球コロニー刺激因子の誘導体化
Kochendoerfer Site-specific polymer modification of therapeutic proteins
AU627694B2 (en) Conjugates of cytokines with immunoglobulins
JP5336372B2 (ja) G−csf部位特異的モノコンジュゲート
US8378073B2 (en) Process for attaching effector molecules to proteins
JP2001526238A (ja) 実質的に純粋なヒスチジン結合タンパク質−ポリマー結合体
JP2009096810A (ja) 成長ホルモンおよび関連タンパク質の誘導体
WO1989009624A1 (en) Solubilization of proteins for pharmaceutical compositions
JP2007532098A (ja) 免疫グロブリン不変領域の量産方法
JP2007533665A (ja) 新規g−csf結合体
EP1128847A1 (en) Antibody-serum protein hybrids
JP2022034075A (ja) オキシム連結のための求核触媒
JP5349501B2 (ja) セレン含有改質剤及びコンジュゲート(Conjugates)
JP2007528347A (ja) 延長された生体内半減期を有するpeg−生理活性ポリペプチド同種二量体結合体及びその製造方法
WO2009113743A1 (ja) Peg化ラクトフェリン複合体及びその製造方法
JPWO1996010089A1 (ja) ペプチド及び蛋白質の修飾